Clinical trial
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
NCT01033422 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
- Lead sponsor
- Can-Fite BioPharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2010
- Completion date
- April 30, 2017
- Enrollment
- 89 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.